Notwithstanding encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. These companies are https://keithlcor088128.blogacep.com/47686636/company-s-medication-faces-is-dealing-with-pbm-hurdles-a-review-of-reimbursement-disputes